Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination.
Coronavirus
decision-making
global survey
parental attitudes
vaccine trials
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
03 06 2021
03 06 2021
Historique:
pubmed:
25
11
2020
medline:
14
5
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented global toll and vaccination is needed to restore healthy living. Timely inclusion of children in vaccination trials is critical. We surveyed caregivers of children seeking care in 17 Emergency Departments (ED) across 6 countries during the peak of the pandemic to identify factors associated with intent to participate in COVID-19 vaccine trials. Questions about child and parent characteristics, COVID-19 expressed concerns and parental attitudes toward participation in a trial were asked.Of 2768 completed surveys, 18.4% parents stated they would enroll their child in a clinical trial for a COVID-19 vaccine and 14.4% would agree to a randomized placebo-controlled study. Factors associated with willingness to participate were parents agreeing to enroll in a COVID-19 vaccine trial themselves (Odds Ratio (OR) 32.9, 95% Confidence Interval (CI) (21.9-51.2)) having an older child (OR 1.0 (1.0-1.01)), having children who received all vaccinations based on their country schedule (OR 2.67 (1.35-5.71)) and parents with high school education or lower (OR 1.79 (1.18-2.74)). Mothers were less likely to enroll their child in a trial (OR 0.68 (0.47-0.97)). Only one fifth of families surveyed will consider enrolling their child in a vaccine trial. Parental interest in participation, history of vaccinating their child, and the child being older all are associated with parents allowing their child to participate in a COVID vaccine trial. This information may help decision-makers and researchers shape their strategies for trial design and participation engagement in upcoming COVID19 vaccination trials.
Identifiants
pubmed: 33228458
doi: 10.1080/21645515.2020.1834325
pmc: PMC8115755
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1607-1611Références
Cancer Nurs. 2010 Jan-Feb;33(1):11-8
pubmed: 19926980
Arch Dis Child. 2006 Feb;91(2):112-6
pubmed: 16246853
Res Nurs Health. 2006 Jun;29(3):223-32
pubmed: 16676342
JAMA Pediatr. 2013 Jun;167(6):561-6
pubmed: 23546617
Qual Health Res. 2007 Mar;17(3):311-22
pubmed: 17301340
Anesthesiology. 2003 Mar;98(3):603-8
pubmed: 12606901
J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):309-13
pubmed: 20479689
Paediatr Nurs. 2007 Oct;19(8):14-8
pubmed: 17970358
PLoS One. 2014 Jul 24;9(7):e102505
pubmed: 25057914
BMC Pediatr. 2007 Mar 09;7:12
pubmed: 17349034
J Clin Oncol. 2002 Apr 15;20(8):2109-17
pubmed: 11956272
J Perinatol. 2002 Jan;22(1):57-63
pubmed: 11840244
J Pediatr. 2003 May;142(5):554-9
pubmed: 12756389
Cancer Pract. 1999 Sep-Oct;7(5):248-56
pubmed: 10687594
PLoS Med. 2010 Nov 09;7(11):e1000368
pubmed: 21085696
Vaccine. 2014 Aug 20;32(37):4708-12
pubmed: 24768580
J Med Ethics. 2011 Sep;37(9):544-51
pubmed: 21478415
J Med Ethics. 1992 Jun;18(2):86-93
pubmed: 1619628
J Pediatr. 2007 Nov;151(5):532-7, 537.e1-5
pubmed: 17961701
Trials. 2016 Jan 09;17:17
pubmed: 26745891